CAS NO: | 216974-75-3 |
生物活性 | Bevacizumab, a humanizedIgG1monoclonal antibody, specifically binds to allVEGF-Aisoforms with high affinity. |
IC50& Target | VEGF[1] |
体外研究 (In Vitro) | Bevacizumab, a humanized monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity, and inhibits its interaction with VEGFR-1 and VEGFR-2[1]. Experimental analysis shows that the EC50of Bevacizumab to bind VEGF analyzed by ELISA is 0.18 μg/mL. Binding kinetics assays show similar results that Bevacizumab inhibits the VEGF-induced proliferation of HUVEC with an IC50value of 0.047±0.0081 μg/mL[2]. |
体内研究 (In Vivo) | It is demonstrated that the subconjunctival administration of FD006 and Bevacizumab can significantly inhibit CoNV in NaOH cauterized rats compared with the control group (p < 0.01)[2]. |
Clinical Trial | |
分子量 | 149 kDa(Average) |
性状 | Liquid |
CAS 号 | 216974-75-3 |
中文名称 | 贝伐珠单抗 |
储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024 |